
## Human Reproduction, pp. 1-1, 2019

doi:10.1093/humrep/dez205

human reproduction

## SUPPLEMENTARY DATA



**Supplementary Figure S3 Validation and initial pharmacological studies in PWA rats as a suitable PCOS model.** Phenotypic characterization of the PWA model, generated in this initial set of studies by continuous DHT administration via a silastic capsule containing 7.5 mg DHT. In panel (**A**), body weight (BW), basal LH, ovarian (OW) and uterus weight (UW), as well as actual DHT levels at the end of the 90-day treatment period, are shown in a representative subset of PWA 7.5 animals (N = 10). In panels (**B**) and (**C**), LH and FSH responses to repeated KP-54 administration are presented at Days I, 4 and 7 after initiation of KP-54 treatments (100 µg/kg, daily s.c. injections) (N = 10). For comparative purposes, acute LH and FSH responses to a single bolus of KP-54 in control female rats are also shown. Note the nearly undetectable basal LH levels, and the severely blunted LH responses to KP-54 in this 7.5-mg DHT PWA model, despite enhanced FSH responses. Finally, in panel (**D**), ovarian responses to daily administration of KP-54 for 7 days in this PWA model are shown (N = 5). Repeated KP-54 administration resulted in trophic ovarian responses, including a decrease in the number of atretic follicles and an increase in the number of healthy follicles of >350 µm of diameter, but did not rescue ovulation. Blue dotted lines represent the mean values obtained in control, non-androgenized female rats, used as reference. In all panels, each histogram represents the mean ± SEM. Data were analyzed by Student *t* tests (in panel A, \*\*\**P* < 0.001 versus control group; in panel D, \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001 versus PNA rats treated with vehicle).